Use of melanocortins to treat insulin sensitivity

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9827286
SERIAL NO

15242866

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IPSEN PHARMA S A S65 QUAI GEORGES GORSE BOULOGNE-BILLANCOURT 92100

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Butler, Andrew A Kirkwood, US 10 21
Culler, Michael DeWitt Hopkinton, US 24 126
Halem, Heather A Westborough, US 8 25

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 28, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 28, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00